Submission to RAC (7/13/88) - Anderson/Blaese/Rosenberg 
Brief Scientific Abstract 
An aliquot of TIL would be removed at the time that they have reached log 
phase growth. The aliquot (representing no more than 1/3 of the total TIL 
population) would be incubated with the retroviral vector N2 (containing the Neo^ 
gene) . This treated aliquot would be grown in G418 until all of the cells 
contain, and are expressing, the Neo^ gene. The cells would be tested to insure 
that they are virus -free, have a similar surface antigen pattern to the parent 
TIL population, and have not changed significantly in their properties (including 
continued dependence on exogenous 11-2 for growth). The treated aliquot would 
then be administered to the patient along with the bulk TIL population that would 
have been grown separately. The proportion of marked TIL in the final TIL 
population that would be returned to the patient would probably be between 5- 
30%. After administration, samples of blood, lymph nodes, and trunor biopsy 
material (already being obtained as part of the standard TIL protocol) would be 
tested for the presence of the Neo^ gene by PCR DNA analysis. The marked TIL 
would be recovered by growth of the tissue sample in TIL medium plus G418. The 
recovered cells would be studied for phenotypic and cytotoxic properties in order 
to attempt to learn why TIL immunotherapy is successful in some cases but not in 
others . 
Recombinant DNA Research, Volume 14 
[23] 
